Schizophrenia as a disorder of too little dopamine: Implications for symptoms and treatment

Expert Review of Neurotherapeutics

Volumn 11, Issue 4, 2011, Pages 589-607

  Remington, Gary ^a,b,c   Agid, Ofer ^a,c   Foussias, George ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Institute of Medical Science   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

antipsychotics; dopamine; schizophrenia; symptoms; treatment

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBIDOPA; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE BETA MONOOXYGENASE; HALOPERIDOL; LEVODOPA; NEUROLEPTIC AGENT; NORADRENALIN; PIMOZIDE; RISPERIDONE; THIORIDAZINE; TYROSINE;

AKINESIA; ANXIETY DISORDER; APATHY; ARCUATE NUCLEUS; CEREBELLUM; COGNITIVE DEFECT; CORPUS CALLOSUM; CORPUS STRIATUM; DELUSION; DEPRESSION; DOPAMINE BRAIN LEVEL; DOPAMINE RECEPTOR BLOCKING; DRUG RECEPTOR BINDING; ENTORHINAL CORTEX; EXTRAPYRAMIDAL SYMPTOM; FRONTAL CORTEX; HALLUCINATION; HUMAN; HYPOPHYSIS; HYPOTHALAMUS; MESOLIMBIC DOPAMINERGIC SYSTEM; NEGATIVE SYNDROME; NEUROMODULATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY BULB; POSITIVE SYNDROME; REVIEW; RIGIDITY; SCHIZOPHRENIA; SUBSTANTIA NIGRA; TREMOR; TUBEROHYPOPHYSEAL TRACT; VENTRAL TEGMENTUM;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOPAMINE; HUMANS; PARKINSON DISEASE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 79953762960     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.191     Document Type: Review

References (260)

1. Healy D. The Creation of Psychopharmacology. Harvard University Press, MA, USA (2002).
2. Carlsson A, Lindqvist M, Magnusson T, Waldeck B. On the presence of 3-hydroxytyramine in brain. Science 127(3296), 471 (1958).
3. Hornykiewicz O. The action of dopamine on the arterial blood pressure of the guinea-pig. Br. J. Pharmacol. Chemother. 13(1), 91-94 (1958).
4. Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov. Disord. 17(3), 501-508 (2002). (Pubitemid 36040962)
5. Montagu KA. Catechol compounds in rat tissues and in brains of different animals. Nature 180(4579), 244-245 (1957).
6. Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol. Psychiatry 32(1), 1-17 (1992).
7. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1(2), 133-152 (1987). (Pubitemid 17119661)
8. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov. Disord. 23(Suppl. 3), S497-S508 (2008).
9. Iversen SD, Iversen LL. Dopamine: 50 years in perspective. Trends Neurosci. 30(5), 188-193 (2007). (Pubitemid 46654233)
10. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol. 67(1), 53-83 (2002). (Pubitemid 34786170)
11. Standaert DG, Galanter JM. Pharmacology of dopaminergic neurotransmission. In: Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Golan DE, Tashjian AJ Jr, Armstrong EJ, Armstrong AW (Eds). Lippincott Williams & Wilkins, NY, USA, 185-206 (2008).
12. Kupfermann I. Modulatory actions of neurotransmitters. Annu. Rev. Neurosci. 2, 447-465 (1979).
13. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialities (CPS). Canadian Pharmacists Association, Ottawa, Canada (2010).
14. Goto Y, Grace AA. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective. Int. Rev. Neurobiol. 78, 41-68 (2007).
15. Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol. 78, 1-39 (2007).
16. Remington G. Alterations of dopamine and serotonin transmission in schizophrenia. Prog. Brain Res. 172, 117-140 (2008).
17. Williams SM, Goldman-Rakic PS. Widespread origin of the primate mesofrontal dopamine system. Cereb. Cortex 8(4), 321-345 (1998). (Pubitemid 28280738)
18. Beauregard M, Ferron A, Descarries L. Opposite effects of neurotensin on dopamine inhibition in different regions of the rat brain: an iontophoretic study. Neuroscience 47(3), 613-619 (1992).
19. Studler JM, Kitabgi P, Tramu G, Herve D, Glowinski J, Tassin JP. Extensive co-localization of neurotensin with dopamine in rat meso-cortico-frontal dopaminergic neurons. Neuropeptides 11(3), 95-100 (1988). (Pubitemid 18095023)
20. Sian J, Gerlach M, Youdim MB, Riederer P. Parkinson's disease: a major hypokinetic basal ganglia disorder. J. Neural Transm. 106(5-6), 443-476 (1999). (Pubitemid 29273885)
21. Mehler-Wex C, Riederer P, Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox. Res. 10(3-4), 167-179 (2006).
22. 2 dopamine receptors leads to an increase in c-fos messenger RNA in cholinergic interneurons and a redistribution of c-fos messenger RNA in striatal projection neurons. Neuroscience 98(4), 749-757 (2000). (Pubitemid 30417591)
23. Piomelli D, Pilon C, Giros B, Sokoloff P, Martres MP, Schwartz JC. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature 353(6340), 164-167 (1991). (Pubitemid 21912481)
24. Capper-Loup C, Canales JJ, Kadaba N, Graybiel AM. Concurrent activation of dopamine D1 and D2 receptors is required to evoke neural and behavioral phenotypes of cocaine sensitization. J. Neurosci. 22(14), 6218-6227 (2002). (Pubitemid 35387662)
25. Scornaiencki R, Cantrup R, Rushlow WJ, Rajakumar N. Prefrontal cortical D1 dopamine receptors modulate subcortical D2 dopamine receptor-mediated stress responsiveness. Int. J. Neuropsychopharmacol. 12(9), 1195-1208 (2009).
26. Lidow MS, Williams GV, Goldman-Rakic PS. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol. Sci. 19(4), 136-140 (1998). (Pubitemid 28218536)
27. 4 dopaminergic receptor interplay mediates coincident G protein-independent and dependent regulation of glutamate NMDA receptors in the lateral amygdala. J. Neurochem. 106(6), 2421-2435 (2008).
28. 1 receptor-mediated NMDA receptor insertion depends on Fyn but not Src kinase pathway in prefrontal cortical neurons. Mol. Brain, 3, 20 (2010).
29. 1 receptors. Synapse 64(11), 870-874 (2010).
30. 1 receptor-mediated enhancement of NMDA receptor trafficking requires rapid PKC-dependent synaptic insertion in the prefrontal neurons. J. Neurochem 114(1), 62-73 (2010).
31. Cho DI, Quan W, Oak MH, Choi HJ, Lee KY, Kim KM. Functional interaction between dopamine receptor subtypes for the regulation of c-fos expression. Biochem. Biophys. Res. Commun. 357(4), 1113-1118 (2007). (Pubitemid 46693685)
32. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 117(2), 690-697 (1985). (Pubitemid 15237891)
33. McDonald WM, Sibley DR, Kilpatrick BF, Caron MG. Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors. Mol. Cell Endocrinol. 36(3), 201-209 (1984). (Pubitemid 14075511)
34. high dopamine receptors. Synapse 60(4), 319-346 (2006). (Pubitemid 44134353)
35. 3H]spiperone in isotonic medium: implications for human positron emission tomography. Synapse 49(4), 209-215 (2003). (Pubitemid 36927961)
36. 11C]-(+)- PHNO. Biol. Psychiatry 59(5), 389-394 (2006). (Pubitemid 43289216)
37. Nikolaus S, Antke C, Muller HW. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav. Brain Res. 204(1), 32-66 (2009).
38. 11C]-(+)-PHNO PET study. Neuropsychopharmacology 34(4), 1078-1086 (2009).
39. 2 receptor in vitro. Synapse 63(11), 998-1009 (2009).
40. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41(1), 1-24 (1991).
41. Allen NC, Bagade S, McQueen MB et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 40(7), 827-834 (2008). (Pubitemid 351913655)
42. Elvevag B, Weinberger DR. Introduction: genes, cognition and neuropsychiatry. Cogn. Neuropsychiatry 14(4-5), 261-276 (2009).
43. Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J. Molecular mechanisms of schizophrenia. Cell. Physiol. Biochem. 20(6), 687-702 (2007). (Pubitemid 350059714)
44. Tan HY, Callicott JH, Weinberger DR. Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. Cogn. Neuropsychiatry 14(4-5), 277-298 (2009).
45. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr. Bull. 35(3), 549-562 (2009).
46. Deniker P. From chlorpromazine to tardive dyskinesia (brief history of neuroleptics). Psychiatr. J. Univ. Ott. 14(1), 253-2259. (1989).
47. Deniker P. The neuroleptics: a historical survey. Acta Physiol. Scand. 82, 83-87 (1990) (Pubitemid 20297826)
48. Remington G, Kapur S. The pharmacology of typical and atypical antipsychotics. In: Drug Induced Movement Disorders. Factor SA, Lang A, Weiner WJ (Eds). Blackwell Futura, MA, USA, 55-71 (2005).
49. Carlsson A, Lindqvist, M. Effect of chlorpormazine or haloperidol on formation of 3-methoxy-tyramine and normetanephrine in mouses brain. Acta Pharmicol. Toxicol. (Copenh.), 20, 140-144 (1963).
50. Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed. Proc. 32(2), 200-205 (1973).
51. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261(5562), 717-719 (1976).
52. Van Rossum J. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Neuropsychopharmacology, Proceedings of the 5th Collegium Internationale Neuro-psychopharmacologicum (CINP). Brill H, Coyle J, Deniker P, Hippius H, Bradley P (Eds). Excerptica Medica, Amsterdam, The Netherlands, 321-329 (1967).
53. Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy 14(5), 543-560 (1994). (Pubitemid 24299954)
54. Singh MM, Kay SR. A longitudinal therapeutic comparison between two prototypic neuroleptics (haloperidol and chlorpromazine) in matched groups of schizophrenics. Nontherapeutic interactions with trihexyphenidyl. Theoretical implications for potency differences. Psychopharmacologia 43(2), 115-121 (1975).
55. FDA approves clozapine for treatment of schizophrenia; careful monitoring required. Hosp. Community Psychiatry 40(12), 1310 (1989).
56. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. 7(Suppl. 1), S1-S5 (2004). (Pubitemid 38436990)
57. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49(7), 538-544 (1992).
58. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157(4), 514-520 (2000). (Pubitemid 30191189)
59. Nordstrom AL, Farde L, Wiesel FA et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry 33(4), 227-235 (1993). (Pubitemid 23091497)
60. 2 receptor occupancy in antipsychotic drug-treated patients. J. Clin. Psychopharmacol. 18(4), 305-310 (1998). (Pubitemid 28353873)
61. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am. J. Psychiatry 159(1), 133-135 (2002).
62. Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J. Psychopharmacol. 22(2 Suppl.), 12-19 (2008).
63. Wolkin A, Barouche F, Wolf AP et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am. J. Psychiatry 146(7), 905-908 (1989). (Pubitemid 19180972)
64. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 50(11), 873-883 (2001). (Pubitemid 34020700)
65. 4 receptors and development of newer antipsychotic drugs. Fundam. Clin. Pharmacol. 14(6), 529-539 (2000). (Pubitemid 32052549)
66. Meador-Woodruff JH. Update on dopamine receptors. Ann. Clin. Psychiatry 6(2), 79-90 (1994). (Pubitemid 24312171)
67. Muir WJ, Thomson ML, McKeon P et al. Markers close to the dopamine D5 receptor gene (DRD5) show significant association with schizophrenia but not bipolar disorder. Am. J. Med. Genet. 105(2), 152-158 (2001). (Pubitemid 32290578)
68. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Curr. Opin. Neurol. Neurosurg, 6(4), 602-608 (1993). (Pubitemid 23232828)
69. 3 receptors are a common site of action for antipsychotic drugs - an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr. Bull. 35(4), 789-797 (2009).
70. Sunahara RK, Seeman P, Van Tol HH, Niznik HB. Dopamine receptors and antipsychotic drug response. Br. J. Psychiatry Suppl. (22), 31-38 (1993). (Pubitemid 23355887)
71. Wong AH, Van Tol HH. The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(7), 1091-1099 (2003). (Pubitemid 37464955)
72. Brenner HD, Dencker SJ, Goldstein MJ et al. Defining treatment refractoriness in schizophrenia. Schizophr. Bull. 16(4), 551-561 (1990).
73. Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. Am. J. Psychiatry 141(6), 748-752 (1984). (Pubitemid 14106358)
74. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry 45(1), 79-91 (1988). (Pubitemid 18018573)
75. Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol. Med. 24(2), 307-316 (1994). (Pubitemid 24158845)
76. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N. Engl. J. Med. 324(11), 746-754 (1991).
77. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist. Psychiatry 18(1), 39-60 (2007).
78. Hippius H. The history of clozapine. Psychopharmacology (Berl.), 99(Suppl.), S3-S5 (1989). (Pubitemid 19244131)
79. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45(9), 789-796 (1988).
80. Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch. Gen. Psychiatry 39(7), 789-794 (1982). (Pubitemid 12090302)
81. Carpenter WT, Jr., Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 145(5), 578-583 (1988).
82. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. Br. J. Psychiatry 137, 383-386 (1980).
83. Remington G, Foussias G, Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs 24(1), 9-20 (2010).
84. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153(3), 321-330 (1996). (Pubitemid 26074706)
85. Greenwood KE, Landau S, Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr. Bull. 31(4), 910-921 (2005). (Pubitemid 41437786)
86. Harvey PD, Koren D, Reichenberg A, Bowie CR. Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr. Bull. 32(2), 250-258 (2006).
87. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry 58(2), 165-171 (2001). (Pubitemid 32142754)
88. Bora E, Yucel M, Pantelis C. Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond. Schizophr. Bull. 36(1), 36-42 (2010).
89. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov. Disord. 24(15), 2175-2186 (2009).
90. Rodriguez-Oroz MC, Jahanshahi M, Krack P et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol. 8(12), 1128-1139 (2009).
91. Oguru M, Tachibana H, Toda K, Okuda B, Oka N. Apathy and depression in Parkinson disease. J. Geriatr. Psychiatry Neurol. 23(1), 35-41 (2010).
92. Pedersen KF, Alves G, Aarsland D, Larsen JP. Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J. Neurol. Neurosurg. Psychiatry 80(11), 1279-1282 (2009).
93. Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Power B. The syndromal validity and nosological position of apathy in Parkinson's disease. Mov. Disord. 24(8), 1211-1216 (2009).
94. Pedersen KF, Alves G, Bronnick K, Aarsland D, Tysnes OB, Larsen JP. Apathy in drug-naive patients with incident Parkinson's disease: the Norwegian ParkWest study. J. Neurol. 257(2), 217-223 (2010).
95. Khoo TK, Burn DJ. Non-motor symptoms may herald Parkinson's disease. Practitioner 253(1721), 19-24, 12 (2009).
96. Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L. Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov. Disord. 24(16), 2391-2397 (2009).
97. Schmidt L, d'Arc BF, Lafargue G et al. Disconnecting force from money: effects of basal ganglia damage on incentive motivation. Brain 131(Pt 5), 1303-1310 (2008).
98. Czernecki V, Schupbach M, Yaici S et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov. Disord. 23(7), 964-969 (2008).
99. Haegelen C, Rouaud T, Darnault P, Morandi X. The subthalamic nucleus is a key structure of limbic basal ganglia functions. Med. Hypotheses 72(4), 421-426 (2009).
100. Le Jeune F, Drapier D, Bourguignon A et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 73(21), 1746-1751 (2009).
101. Porat O, Cohen OS, Schwartz R, Hassin-Baer S. Association of preoperative symptom profile with psychiatric symptoms following subthalamic nucleus stimulation in patients with Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 21(4), 398-405 (2009).
102. Van Putten T, May PR, Marder SR, Wittmann LA. Subjective response to antipsychotic drugs. Arch. Gen. Psychiatry 38(2), 187-190 (1981). (Pubitemid 11142771)
103. Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr. Res. 85(1-3), 222-231 (2006). (Pubitemid 43947541)
104. Booij L, Van der Does AJ, Riedel WJ. Monoamine depletion in psychiatric and healthy populations: review. Mol. Psychiatry 8(12), 951-973 (2003). (Pubitemid 37523908)
105. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 12(4), 331-359 (2007). (Pubitemid 46496835)
106. Boot E, Booij J, Hasler G et al. AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. Eur. J. Nucl. Med. Mol. Imaging 35(7), 1350-1356 (2008).
107. Verhoeff N, Christensen BK, Hussey D et al. Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacol. Biochem. Behav. 74, 425-432 (2003). (Pubitemid 35449529)
108. Verhoeff NP, Hussey D, Lee M et al. Dopamine depletion results in increased neostriatal D2, but not D1, receptor binding in humans. Mol. Psychiatry 7(3), 233, 322-238 (2002). (Pubitemid 34280629)
109. 2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 25(2), 213-223 (2001). (Pubitemid 32566343)
110. 2 binding ratios on SPECT imaging. Neuropsychopharmacology 25(5), 642-650 (2001). (Pubitemid 32995946)
111. Voruganti LN, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia - findings from an in vivo SPECT study. Schizophr. Res. 88(1-3), 179-186 (2006). (Pubitemid 44693241)
112. 18F] fallypride. Biol. Psychiatry 63(2), 241-244 (2008). (Pubitemid 350299319)
113. Bremner JD, Vythilingam M, Ng CK et al. Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA 289(23), 3125-3134 (2003). (Pubitemid 37432888)
114. Hasler G, Luckenbaugh DA, Snow J et al. Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder. Biol. Psychiatry 66(3), 201-205 (2009).
115. 2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J. Neurosci. 22(1), 294-304 (2002). (Pubitemid 34033507)
116. Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, Watson SJ. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15(1), 17-29 (1996). (Pubitemid 26233387)
117. 18F]fluorodopa positron emission tomographic study. Arch. Neurol. 57(4), 470-475 (2000). (Pubitemid 30212118)
118. Nobili F, Campus C, Arnaldi D et al. Cognitive-nigrostriatal relationships in de novo, drug-naive Parkinson's disease patients: a [I-123]FP-CIT SPECT study. Mov. Disord. 25(1), 35-43 (2010).
119. Simpson EH, Kellendonk C, Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65(5), 585-596 (2010).
120. Kulisevsky J, Garcia-Sanchez C, Berthier ML et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov. Disord. 15(4), 613-626 (2000). (Pubitemid 30479613)
121. Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 7(10), 927-938 (2008).
122. Hawkins KA, Keefe RS, Christensen BK et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophr. Res. 105(1-3), 1-9 (2008).
123. Jahshan C, Heaton RK, Golshan S, Cadenhead KS. Course of neurocognitive deficits in the prodrome and first episode of schizophrenia. Neuropsychology 24(1), 109-120 (2010).
124. Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am. J. Psychiatry 156(9), 1336-1341 (1999). (Pubitemid 29416528)
125. Belmaker RH, Wald D. Haloperidol in normals. Br. J. Psychiatry 131, 222-223 (1977).
126. de Visser SJ, van der Post J, Pieters MS, Cohen AF, van Gerven JM. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br. J. Clin. Pharmacol. 51(2), 119-132 (2001). (Pubitemid 32219735)
127. 1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl.) 174(1), 3-16 (2004). (Pubitemid 38925085)
128. 11C]SCH23390 in patients with chronic schizophrenia. Life Sci. 86(21-22), 814-818 (2010).
129. Aleman A, EH FdH, Castner SA, Williams GV, Goldman-Rakic PS. Antipsychotics and working memory in schizophrenia. Science 289(5476), 56b-58b (2000).
130. 1 receptor stimulation. Science 287(5460), 2020-2022 (2000). (Pubitemid 30158679)
131. Costa A, Peppe A, Dell'Agnello G, Caltagirone C, Carlesimo GA. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 47(5), 1374-1381 (2009).
132. Hsieh PC, Yeh TL, Lee IH et al. Correlation between errors on the Wisconsin Card Sorting Test and the availability of striatal dopamine transporters in healthy volunteers. J. Psychiatry Neurosci. 35(2), 90-94 (2010).
133. Abi-Dargham A. Recent evidence for dopamine abnormalities in schizophrenia. Eur. Psychiatry 17, 341-347 (2002). (Pubitemid 34987832)
134. Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. Int. Rev. Neurobiol. 78, 133-164 (2007).
135. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44(7), 660-669 (1987). (Pubitemid 17099795)
136. Weinberger DR. Schizophrenia, the prefrontal cortex, and a mechanism of genetic susceptibility. Eur. Psychiatry 17, 355-363 (2002).
137. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther. 113(2), 296-320 (2007). (Pubitemid 46149046)
138. Kraepelin E. Dementia Praecox and Paraphrenia. Krieger Publishing Co., FL, USA (1971).
139. Archer T. Neurodegeneration in schizophrenia. Expert Rev. Neurother. 10(7), 1131-1141 (2010).
140. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry 46(6), 729-739 (1999). (Pubitemid 29460898)
141. Rund BR. Is there a degenerative process going on in the brain of people with schizophrenia? Front. Hum. Neurosci. 3, 36 (2009).
142. Waddington JL, Lane A, Scully P et al. Early cerebro-craniofacial dysmorphogenesis in schizophrenia: a lifetime trajectory model from neurodevelopmental basis to 'neuroprogressive' process. J. Psychiatr. Res. 33(6), 477-489 (1999).
143. Waddington JL, Lane A, Scully PJ, Larkin C, O'Callaghan E. Neurodevelopmental and neuroprogressive processes in schizophrenia. Antithetical or complementary, over a lifetime trajectory of disease? Psychiatr. Clin. North Am. 21(1), 123-149 (1998). (Pubitemid 28172913)
144. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 35(3), 528-548 (2009).
145. Pantelis C, Yucel M, Wood SJ et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr. Bull. 31(3), 672-696 (2005). (Pubitemid 41253318)
146. Palmer BW, Heaton SC, Jeste DV. Older patients with schizophrenia: challenges in the coming decades. Psychiatr. Serv. 50(9), 1178-1183 (1999). (Pubitemid 29409968)
147. Bleuler E. Dementia Praecox or the Group of Schizophrenias. International Universities Press, NY, USA (1950).
148. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 22(2), 353-370 (1996). (Pubitemid 26174579)
149. Holland J, Shakhmatova-Pavlova IV. Concept and classification of schizophrenia in the Soviet Union. Schizophr. Bull. 3(2), 277-287 (1977). (Pubitemid 8140162)
150. Hafner H, an der Heiden W. Epidemiology of schizophrenia. Can. J. Psychiatry 42(2), 139-151 (1997). (Pubitemid 27181944)
151. Yung A. Identification and treatment of the prodromal phase of psychotic disorders: perspectives from the PACE Clinic. Early Inter. Psychiatry 1, 224-235 (2007).
152. Addington J, Addington D. Three-year outcome of treatment in an early psychosis program. Can. J. Psychiatry 54(9), 626-630 (2009).
153. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr. Scand. 115(2), 93-100 (2007). (Pubitemid 46114869)
154. Galletly C. Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology (Berl.) 202(1-3), 259-273 (2009).
155. Marder SR. Drug initiatives to improve cognitive function. J. Clin. Psychiatry 67(Suppl. 9), 31-35 (2006). (Pubitemid 44369653)
156. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry 197(3), 174-179 (2010).
157. Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr. Scand. 115(1), 4-11 (2007). (Pubitemid 44973546)
158. Foussias G, Mann S, Zakzanis KK, van Reekum R, Remington G. Motivational deficits as the central link to functioning in schizophrenia: a pilot study. Schizophr. Res. 115(2-3), 333-337 (2009).
159. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's Razor. Schizophr. Bull. 36(2), 359-369 (2010).
160. Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia. Expert Opin. Emerg. Drugs 13(3), 479-495 (2008).
161. Lieberman JA, Drake RE, Sederer LI et al. Science and recovery in schizophrenia. Psychiatr. Serv. 59(5), 487-496 (2008).
162. Hans SL, Auerbach JG, Nuechterlein KH et al. Neurodevelopmental factors associated with schizotypal symptoms among adolescents at risk for schizophrenia. Dev. Psychopathol. 21(4), 1195-1210 (2009).
163. Reichenberg A, Caspi A, Harrington H et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am. J. Psychiatry 167(2), 160-169 (2010).
164. Sorensen HJ, Mortensen EL, Schiffman J, Reinisch JM, Maeda J, Mednick SA. Early developmental milestones and risk of schizophrenia: a 45-year follow-up of the Copenhagen Perinatal Cohort. Schizophr. Res. 118(1-3), 41-47 (2010).
165. Chouinard G, Jones BD. Schizophrenia as dopamine-deficiency disease. Lancet 2(8080), 99-100 (1978). (Pubitemid 8379641)
166. Bertolino A, Esposito G, Callicott JH et al. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. Am. J. Psychiatry 157(1), 26-33 (2000). (Pubitemid 30027417)
167. Callicott JH, Bertolino A, Egan MF, Mattay VS, Langheim FJ, Weinberger DR. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am. J. Psychiatry 157(10), 1646-1651 (2000).
168. 11C]NNC112 and PET. Mol. Psychiatry 13(8), 821-827 (2008). (Pubitemid 352032110)
169. de Frias CM, Annerbrink K, Westberg L, Eriksson E, Adolfsson R, Nilsson LG. Catechol-O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults. J. Cogn. Neurosci. 17, 1018-1025 (2006).
170. Pelayo-Teran JM, Perez-Iglesias R, Vazquez-Bourgon J et al. Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. Psychiatry Res. 185(1-2), 286-289 (2011).
171. Wang CY, Yu-tao X, Cai ZJ et al. Risperidone maintenance treatment in schizophrenia: a randomized controlled trial. Am. J. Psychiatry 167(6), 676-685 (2010).
172. Pelayo-Teran JM, Perez-Iglesias R, Mata I, Carrasco-Marin E, Vazquez-Barquero JL, Crespo-Facorro B. Catechol-O-methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: clinical-onset implications. Psychiatry Res. 179(3), 291-296 (2010).
173. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148(11), 1474-1486 (1991).
174. Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin. Neurosci. 8(1), 137-142 (2006).
175. Boshes RA, Manschreck TC. Review of antipsychotic medication administration: a proposal of intermittent dosing. Schizophr. Bull. 28(2), 203-222 (2002). (Pubitemid 35462238)
176. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl.) 171(2), 121-132 (2004). (Pubitemid 38134648)
177. Braw Y, Bloch Y, Mendelovich S et al. Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients. Schizophr. Bull. 34(3), 544-554 (2008).
178. Harvey PD. When does cognitive decline occur in the period prior to the first episode of schizophrenia? Psychiatry (Edgmont) 6(7), 12-14 (2009).
179. Irani F, Kalkstein S, Moberg EA, Moberg PJ. Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. Schizophr. Bull. DOI: 10.1093/schbul/ sbq057 (2010) (Epub ahead of print).
180. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321(7273), 1371-1376 (2000).
181. Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch. Gen. Psychiatry 63(10), 1079-1087 (2006). (Pubitemid 44498387)
182. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005). (Pubitemid 41345943)
183. Lewis SW, Barnes TR, Davies L et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 32(4), 715-723 (2006). (Pubitemid 44412859)
184. McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163(4), 600-610 (2006). (Pubitemid 44464569)
185. 2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry 158(3), 360-369 (2001). (Pubitemid 32205190)
186. 2 receptor occupancy. Arch. Gen. Psychiatry 57(6), 553-559 (2000). (Pubitemid 30349435)
187. Remington G, Seeman P, Shammi C, Mann S, Kapur S. 'Extended' antipsychotic dosing: rationale and pilot data. J. Clin. Psychopharmacol. 25(6), 611-613 (2005). (Pubitemid 41669063)
188. 2 receptor occupancy for the management of schizophrenia. J. Clin. Psychiatry 69(8), 1281-1286 (2008).
189. 1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J. Psychopharmacol. 22(8), 904-909 (2008).
190. Selemon LD, Begovic A, Goldman-Rakic PS, Castner SA. Amphetamine sensitization alters dendritic morphology in prefrontal cortical pyramidal neurons in the non-human primate. Neuropsychopharmacology 32(4), 919-931 (2007). (Pubitemid 46426180)
191. 1 antagonist. Pharmacol. Biochem. Behav. 96(3), 325-332 (2010).
192. Castner SA, Vosler PS, Goldman-Rakic PS. Amphetamine sensitization impairs cognition and reduces dopamine turnover in primate prefrontal cortex. Biol. Psychiatry 57(7), 743-751 (2005). (Pubitemid 40487918)
193. Meyer-Lindenberg A, Miletich RS, Kohn PD et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 5(3), 267-271 (2002). (Pubitemid 34171141)
194. Keshavan MS, Anderson S, Pettegrew JW. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J. Psychiatr. Res. 28(3), 239-265 (1994). (Pubitemid 24195531)
195. Lavin A, Moore HM, Grace AA. Prenatal disruption of neocortical development alters prefrontal cortical neuron responses to dopamine in adult rats. Neuropsychopharmacology 30(8), 1426-1435 (2005). (Pubitemid 41153114)
196. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17(4), 205-229 (1997). (Pubitemid 27440642)
197. Lodge DJ, Grace AA. Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia. Neurotox. Res. 14(2-3), 97-104 (2008).
198. Paus T, Keshavan M, Giedd JN. Why do many psychiatric disorders emerge during adolescence? Nat. Rev. Neurosci. 9(12), 947-957 (2008).
199. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol. Psychiatry 65(12), 1091-1093 (2009).
200. Lyon GJ, Abi-Dargham A, Moore H, Lieberman JA, Javitch JA, Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr. Bull. 37(1), 108-117 (2011).
201. 1 receptors tell us? World Psychiatry 2(3), 166-171 (2003).
202. Jay TM, Rocher C, Hotte M, Naudon L, Gurden H, Spedding M. Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: importance for psychiatric diseases. Neurotox. Res. 6(3), 233-244 (2004).
203. Owesson-White CA, Cheer JF, Beyene M, Carelli RM, Wightman RM. Dynamic changes in accumbens dopamine correlate with learning during intracranial self-stimulation. Proc. Natl Acad. Sci. USA 105(33), 11957-11962 (2008).
204. Cheer JF, Aragona BJ, Heien ML, Seipel AT, Carelli RM, Wightman RM. Coordinated accumbal dopamine release and neural activity drive goal-directed behavior. Neuron 54(2), 237-244 (2007). (Pubitemid 46561202)
205. Javitt DC. Glycine transport inhibitors and the treatment of schizophrenia. Biol. Psychiatry 63(1), 6-8 (2008). (Pubitemid 350234898)
206. 1 receptor agonists. Psychopharmacology (Berl.) 210(3), 407-418 (2010).
207. 1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology (Berl.) 185(1), 29-35 (2006). (Pubitemid 43289610)
208. Youngren KD, Inglis FM, Pivirotto PJ et al. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20(5), 403-412 (1999). (Pubitemid 29123868)
209. 1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J. Neurophysiol. 87(5), 2324-2336 (2002). (Pubitemid 34670705)
210. 5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J. Pharmacol. Exp. Ther. 281(1), 597-603 (1997). (Pubitemid 27203120)
211. Daniel DG, Weinberger DR, Jones DW et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J. Neurosci. 11(7), 1907-1917 (1991).
212. Goldberg TE, Bigelow LB, Weinberger DR, Daniel DG, Kleinman JE. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am. J. Psychiatry 148(1), 78-84 (1991).
213. Pietrzak RH, Snyder PJ, Maruff P. Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum. Psychopharmacol. 25(4), 353-358 (2010).
214. Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst. Rev. (3), CD006617 (2008).
215. 18F]fallypride PET study. Am. J. Psychiatry 165(8), 988-995 (2008).
216. Janicak PG, Glick ID, Marder SR et al. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J. Clin. Psychiatry 70(1), 25-35 (2009).
217. Komossa K, Rummel-Kluge C, Schmid F et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (4), CD006569 (2009).
218. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin. Ther. 32(Suppl. 1), S3-S20 (2010).
219. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol. Psychiatry 46(10), 1388-1395 (1999).
220. Carlsson ML, Carlsson A, Nilsson M. Schizophrenia: from dopamine to glutamate and back. Curr. Med. Chem. 11(3), 267-277 (2004). (Pubitemid 38240207)
221. Mehta MA, Riedel WJ. Dopaminergic enhancement of cognitive function. Curr. Pharm. Des. 12(20), 2487-2500 (2006).
222. 1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr. Res. 94(1-3), 332-341 (2007). (Pubitemid 47039290)
223. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr. Pharm. Des. 15(22), 2550-2559 (2009).
224. Micheli F, Heidbreder C. Selective dopamine D3 receptor antagonists: a review 2001-2005. Recent Pat. CNS Drug Discov. 1(3), 271-288 (2006).
225. Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr. Bull. DOI: 10.1093/schbul/ sbp149 (2009) (Epub ahead of print).
226. Yamin S, Vaddadi K. Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine. Int. Rev. Psychiatry 22(2), 138-147 (2010).
227. 11C]-raclopride PET study in cats. Neuropsychopharmacology 34(3), 662-671 (2009).
228. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol. Psychiatry 64(2), 145-152 (2008).
229. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. 'Breakthrough' dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 27(11), 2979-2986 (2007). (Pubitemid 46438984)
230. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am. J. Psychiatry 156(3), 412-418 (1999). (Pubitemid 29124163)
231. Mezler M, Geneste H, Gault L, Marek GJ. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr. Opin. Investig. Drugs 11(7), 833-845 (2010).
232. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 68(16), 2269-2292 (2008).
233. Emsley R. Drugs in development for the treatment of schizophrenia. Expert Opin. Investig. Drugs 18(8), 1103-1118 (2009).
234. McGlashan TH. Is active psychosis neurotoxic? Schizophr. Bull. 32(4), 609-613 (2006).
235. Mihalopoulos C, Harris M, Henry L, Harrigan S, McGorry P. Is early intervention in psychosis cost-effective over the long term? Schizophr. Bull. 35(5), 909-918 (2009).
236. Liu CC, Sheu YH, Wu SY, Lai MC, Hwu HG. Rapid response to antipsychotic treatment on psychotic prodrome: implications from a case series. Psychiatry Clin. Neurosci. 64(2), 202-206 (2010).
237. McGorry PD, Nelson B, Amminger GP et al. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J. Clin. Psychiatry 70(9), 1206-1212 (2009).
238. Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Intervention in the at-risk state to prevent transition to psychosis. Curr. Opin. Psychiatry 22(2), 177-183 (2009).
239. Walker EF, Cornblatt BA, Addington J et al. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr. Res. 115(1), 50-57 (2009).
240. Hashimoto K. Can the σ-1 receptor agonist fluvoxamine prevent schizophrenia? CNS Neurol. Disord. Drug Targets. 8(6), 470-474 (2009).
241. Muller N, Myint AM, Schwarz MJ. The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment. Dialogues Clin. Neurosci. 11(3), 319-332 (2009).
242. Ritsner MS. Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials. CNS Neurosci. Ther. 16(1), 32-44 (2010).
243. Bota RG, Sagduyu K, Filin EE, Bota DA, Munro S. Toward a better identification and treatment of schizophrenia prodrome. Bull. Menninger. Clin. 72(3), 210-227 (2008).
244. Cannon TD, Cadenhead K, Cornblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 65(1), 28-37 (2008).
245. Mitchell KJ, Porteous DJ. Rethinking the genetic architecture of schizophrenia. Psychol. Med. 1-14 (2010).
246. Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum. Psychopharmacol. 25(2), 179-186 (2010).
247. Wolff-Menzler C, Hasan A, Malchow B, Falkai P, Wobrock T. Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry 43(4), 122-129 (2010).
248. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr. Opin. Psychiatry 23(2), 103-111 (2010).
249. Mouaffak F, Tranulis C, Gourevitch R et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin. Neuropharmacol. 29(1), 28-33 (2006). (Pubitemid 44378609)
250. Remington G. Augmenting clozapine response in treatment-resistant schizophrenia. In: Therapy-Resistant Schizophrenia. Elkis H, Meltzer HY (Eds). Karger, Basel, 129-151 (2010).
251. Harvey PD, McClure MM. Pharmacological approaches to the management of cognitive dysfunction in schizophrenia. Drugs 66(11), 1465-1473 (2006).
252. Dean B, Scarr E. Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits. Curr. Drug Targets CNS Neurol. Disord. 3(3), 217-225 (2004). (Pubitemid 38854916)
253. Hoff AL, Faustman WO, Wieneke M et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 15(4), 361-369 (1996). (Pubitemid 26342919)
254. Laughren T, Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr. Bull. 32(2), 220-222 (2006).
255. Harvey PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol. Rev. 19(3), 324-335 (2009).
256. Livingstone PD, Srinivasan J, Kew JN et al. α7 and non-α7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur. J. Neurosci. 29(3), 539-550 (2009).
257. Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD. Cognitive improvement by activation of α7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr. Pharm. Des. 16(3), 323-343 (2010).
258. Wallace TL, Callahan PM, Tehim A et al. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 336(1), 242-253. (2011).
259. Gottesman, II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160(4), 636-645 (2003). (Pubitemid 41079594)
260. Thaker GK. Schizophrenia endophenotypes as treatment targets. Expert Opin. Ther. Targets 11(9), 1189-1206 (2007).